Major bleeding events: unfractionated heparin · kidney transplant recipients
Heparin showed no clear difference in major bleeding events: unfractionated heparin compared with placebo (low certainty).
1 finding from 1 review
Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
PE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in PE at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (7 days ‐ 12 months) compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
All‐cause mortality (5 days to 12 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (5 days to 12 months) compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in PE at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (3 months) compared with low molecular weight heparin (low certainty).
1 finding from 1 review
All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Total VTE · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
It is very uncertain whether unfractionated heparin changes DVT (symptomatic, asymptomatic, non‐fatal) (5 to 8 days after surgery) compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
PE (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All cause mortality · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found